32 results
6-K
EX-99.2
PBM
Psyence Biomedical Ltd. Warrant
20 Sep 24
Share Purchase and Sale Agreement
5:00pm
this acquisition, which gives us access to state-of-the-art cultivation and production capabilities that support our goal of becoming a leading, vertically … statements regarding the fulfilment of the conditions to the closing of the Proposed Acquisition, access to the capital and liquidity required
6-K
EX-99.1
PBM
Psyence Biomedical Ltd. Warrant
5 Sep 24
Current report (foreign)
4:31pm
Product within the Fields of Use.
6.3.
Access.
Except as set out in Section 2.2, PBM shall not provide the Licensed IP to a third party nor allow … access to the Licensed IP by a third party. Notwithstanding the foregoing, the Licensed IP may be provided only to:
those of PBM employees
424B3
PBM
Psyence Biomedical Ltd. Warrant
30 Aug 24
Prospectus supplement
4:00pm
trials, PEX010 is also already being administered to real-world patients via the Health Canada Special Access Program (“SAP”). Through the SAP, PEX010 … parties to leverage or access these capabilities;
the amount and timing of sales and other revenues from Psyence’s product candidates, if approved
F-1
PBM
Psyence Biomedical Ltd. Warrant
19 Aug 24
Registration statement (foreign)
4:07pm
Access Program (“SAP”). Through the SAP, PEX010 is being prescribed for end of life distress as well as Major Depressive Disorder.
As of July 17 … or access these capabilities;
the amount and timing of sales and other revenues from Psyence’s product candidates, if approved, including the sales
424B3
PBM
Psyence Biomedical Ltd. Warrant
19 Aug 24
Prospectus supplement
9:27am
Access Program (“SAP”). Through the SAP, PEX010 is being prescribed for end of life distress as well as Major Depressive Disorder.
As of July 17, 2024 … with third parties to leverage or access these capabilities;
the amount and timing of sales and other revenues from Psyence’s product candidates
POS AM
mxs8y6991
12 Aug 24
Prospectus update (post-effective amendment)
5:23pm
6-K
EX-99.3
pyk zxvcmeuxn543x
31 Jul 24
Common Stock Purchase Agreement
4:11pm
6-K
EX-99.1
euvvmznp2w
31 Jul 24
Common Stock Purchase Agreement
4:11pm
F-1/A
hc39j367o47maw8yax
6 May 24
Registration statement (foreign) (amended)
8:27pm
F-1/A
onad5nux 1srbzms
18 Apr 24
Registration statement (foreign) (amended)
6:03am
6-K
EX-99.2
064146y trux7zsya
12 Mar 24
Psyence Group's NASDAQ Listed Associate, Psyence Biomedical, Receives Human Research Ethics Committee (HREC) Approval to Initiate Phase IIb Study
5:25pm
F-1
mac0wowo6 pqxli70
9 Feb 24
Registration statement (foreign)
4:09pm
20-F
EX-4.16
1h7z9p7 q5p49
31 Jan 24
Annual report (foreign)
5:05pm
20-F
yol2cba4dj1bsrc e86k
31 Jan 24
Annual report (foreign)
5:05pm
425
y5g6ok
22 Jan 24
Business combination disclosure
9:53pm
425
EX-10.1
05qurxi
17 Jan 24
Business combination disclosure
6:00am
425
EX-99.1
65i9 pmh2a5kwb
17 Jan 24
Business combination disclosure
6:00am